Takeaway
A 21-mRNA signature was identified to predict the survival of individuals with lower‑grade gliomas (LGGs).
Why this matters
Overall survival varies greatly between individuals with LGGs, highlighting the importance of evaluating exact outcomes to facilitate individualized clinical management. This study identified an mRNA-based prognostic signature that may facilitate the effective stratification and individualized management of patients.